4.6 Article

Comparison of Blood RNA Extraction Methods Used for Gene Expression Profiling in Amyotrophic Lateral Sclerosis

Journal

PLOS ONE
Volume 9, Issue 1, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0087508

Keywords

-

Funding

  1. European Union [259867]
  2. EU
  3. France, Agence Nationale de la Recherche (ANR)
  4. Germany, Bundesministerium fur Bildung und Forschung (BMBF)
  5. Ireland, Health Research Board (HRB)
  6. Italy, Ministero della Salute
  7. Netherlands, The Netherlands Organisation for Health Research and Development (ZonMw)
  8. Poland, Narodowe Centrum Badan i Rozwoju
  9. Portugal, Fundacao a Ciencia e a Tecnologia
  10. Spain, Ministerio de Ciencia e Innovacion
  11. Switzerland, Schweizerischer Nationalfonds zur Forderung der wissenschaftlichen Forschung (SNF)
  12. Turkey, Tubitak
  13. United Kingdom, Medical Research Council (MRC)
  14. MND Association/MRC Lady Edith Wolfson Fellowship [MR/K003771/1]
  15. MRC PhD studentship
  16. NIHR
  17. MRC [MR/K003771/1, MR/K000039/1] Funding Source: UKRI
  18. Medical Research Council [MR/K000039/1, MR/K003771/1] Funding Source: researchfish
  19. National Institute for Health Research [NF-SI-0512-10082] Funding Source: researchfish

Ask authors/readers for more resources

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes death within a mean of 2-3 years from symptom onset. There is no diagnostic test and the delay from symptom onset to diagnosis averages 12 months. The identification of prognostic and diagnostic biomarkers in ALS would facilitate earlier diagnosis and faster monitoring of treatments. Gene expression profiling (GEP) can help to identify these markers as well as therapeutic targets in neurological diseases. One source of genetic material for GEP in ALS is peripheral blood, which is routinely accessed from patients. However, a high proportion of globin mRNA in blood can mask important genetic information. A number of methods allow safe collection, storage and transport of blood as well as RNA stabilisation, including the PAXGENE and TEMPUS systems for the collection of whole blood and LEUKOLOCK which enriches for the leukocyte population. Here we compared these three systems and assess their suitability for GEP in ALS. We collected blood from 8 sporadic ALS patients and 7 controls. PAXGENE and TEMPUS RNA extracted samples additionally underwent globin depletion using GlobinClear. RNA was amplified and hybridised onto Affymetrix U133 Plus 2.0 arrays. Lists of genes differentially regulated in ALS patients and controls were created for each method using the R package PUMA, and RT-PCR validation was carried out on selected genes. TEMPUS/GlobinClear, and LEUKOLOCK produced high quality RNA with sufficient yield, and consistent array expression profiles. PAXGENE/GlobinClear yield and quality were lower. Globin depletion for PAXGENE and TEMPUS uncovered the presence of over 60% more transcripts than when samples were not depleted. TEMPUS/GlobinClear and LEUKOLOCK gene lists respectively contained 3619 and 3047 genes differentially expressed between patients and controls. Real-time PCR validation revealed similar reliability between these two methods and gene ontology analyses revealed similar pathways differentially regulated in disease compared to controls.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available